title: Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.
abstract: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, which accounts for approximately 3% of cases of breast malignancies. Diagnosis relies largely on its clinical presentation, and despite a characteristic phenotype, underlying molecular mechanisms are poorly understood. Unique clinical presentation indicates that IBC is a distinct clinical and biological entity when compared to non-IBC. Biological understanding of non-IBC has been extrapolated into IBC and targeted therapies for HER2 positive (HER2+) and hormonal receptor positive non-IBC led to improved patient outcomes in the recent years. This manuscript reviews recent discoveries related to the underlying biology of IBC, clinical progress to date and suggests rational approaches for investigational therapies.
authors.affiliation: Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Costa
authors.affiliation: Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America.
authors.forename: Cesar A
authors.initials: CA
authors.lastname: Santa-Maria
authors.affiliation: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Rossi
authors.affiliation: Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America.
authors.forename: Benedito A
authors.initials: BA
authors.lastname: Carneiro
authors.affiliation: Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America.
authors.forename: Young Kwang
authors.initials: YK
authors.lastname: Chae
authors.affiliation: Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America.
authors.forename: William J
authors.initials: WJ
authors.lastname: Gradishar
authors.affiliation: Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America.
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
authors.affiliation: Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America.|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America.
authors.forename: Massimo
authors.initials: M
authors.lastname: Cristofanilli
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D057170:Translational Research, Biomedical / Q000379:methods / Q000639:trends; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D042461:Vascular Endothelial Growth Factor A
keywords: immunotherapy; inflammatory breast cancer; targeted therapy